US Geothermal (AMEX:HTM) “Buy” Rating Maintained by Analysts at Cowen & Co.; With $6.0 Target; BIORESTORATIVE THERAPIES (BRTX) Sellers Decreased By 40.48% Their Shorts

August 21, 2017 - By Michael Collier

Among 5 analysts covering U S Geothermal (AMEX:HTM), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. U S Geothermal has $6 highest and $0.90 lowest target. $3.55’s average target is -14.66% below currents $4.16 stock price. U S Geothermal had 7 analyst reports since March 29, 2016 according to SRatingsIntel. As per Monday, August 14, the company rating was maintained by Northland Capital. Cowen & Co maintained US Geothermal Inc (NYSEMKT:HTM) on Friday, August 18 with “Buy” rating. Roth Capital initiated US Geothermal Inc (NYSEMKT:HTM) rating on Tuesday, March 29. Roth Capital has “Buy” rating and $0.90 target. As per Friday, November 11, the company rating was upgraded by Raymond James. On Monday, April 25 the stock rating was initiated by Aegis Capital with “Buy”. The rating was maintained by Cowen & Co on Monday, July 17 with “Buy”.

BIORESTORATIVE THERAPIES INCORPORATED (OTCMKTS:BRTX) had a decrease of 40.48% in short interest. BRTX’s SI was 2,500 shares in August as released by FINRA. Its down 40.48% from 4,200 shares previously. With 5,100 avg volume, 1 days are for BIORESTORATIVE THERAPIES INCORPORATED (OTCMKTS:BRTX)’s short sellers to cover BRTX’s short positions. It closed at $3.5 lastly. It is down 0.00% since August 21, 2016 and is . It has underperformed by 16.70% the S&P500.

The stock decreased 0.48% or $0.02 on August 18, reaching $4.16. About 7,396 shares traded. US Geothermal Inc (AMEX:HTM) has declined 12.72% since August 21, 2016 and is downtrending. It has underperformed by 29.42% the S&P500.

U.S. Geothermal Inc. is engaged in the renewable green energy business. The company has market cap of $80.04 million. The Company, through its subsidiary U.S. It has a 152.55 P/E ratio. Geothermal Inc. , is engaged in the acquisition, development and utilization of geothermal resources in the Western United States and the Republic of Guatemala.

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols, involving adult stem cells. The company has market cap of $19.50 million. The Firm offers human and plant stem cell derived cosmetic and skin care products. It currently has negative earnings. The Company’s programs relate to the treatment of disc/spine disease and metabolic disorders and include Disc/Spine Program (brtxDISC) and Metabolic Program (ThermoStem).